ATE297204T1 - Heilmittel für neurodegenerative krankheiten - Google Patents
Heilmittel für neurodegenerative krankheitenInfo
- Publication number
- ATE297204T1 ATE297204T1 AT98961430T AT98961430T ATE297204T1 AT E297204 T1 ATE297204 T1 AT E297204T1 AT 98961430 T AT98961430 T AT 98961430T AT 98961430 T AT98961430 T AT 98961430T AT E297204 T1 ATE297204 T1 AT E297204T1
- Authority
- AT
- Austria
- Prior art keywords
- neurodegenerative diseases
- remedies
- disease
- medicament
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP36931397 | 1997-12-26 | ||
PCT/JP1998/005757 WO1999033465A1 (en) | 1997-12-26 | 1998-12-21 | Remedy for neurodegenerative diseases___________________________ |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE297204T1 true ATE297204T1 (de) | 2005-06-15 |
Family
ID=18494113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98961430T ATE297204T1 (de) | 1997-12-26 | 1998-12-21 | Heilmittel für neurodegenerative krankheiten |
Country Status (12)
Country | Link |
---|---|
US (1) | US6342515B1 (de) |
EP (1) | EP1040830B1 (de) |
JP (1) | JP3364481B2 (de) |
KR (1) | KR100508393B1 (de) |
CN (1) | CN1149084C (de) |
AT (1) | ATE297204T1 (de) |
CA (1) | CA2317044C (de) |
DE (1) | DE69830512T2 (de) |
ES (1) | ES2244103T3 (de) |
HK (1) | HK1029043A1 (de) |
PT (1) | PT1040830E (de) |
WO (1) | WO1999033465A1 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1332363A4 (de) * | 2000-10-09 | 2007-08-29 | Kay Double | Nachweis neurodegenerativer erkrankungen |
US7109198B2 (en) * | 2002-05-17 | 2006-09-19 | Duke University | Method for treating obesity |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
EP1539145A2 (de) * | 2002-09-13 | 2005-06-15 | Eisai Co., Ltd. | Verfahren zur behandlung von tremor |
US20050059718A1 (en) * | 2003-02-21 | 2005-03-17 | Hayato Miyachi | Methods of using zonisamide as an adjunctive therapy for partial seizures |
EP2316456B1 (de) | 2003-04-29 | 2017-06-14 | Orexigen Therapeutics, Inc. | Zubereitungen enthaltend einen Opioidantagonisten und Bupropion zur Beeinflussung von Gewichtsverlust |
US20050043773A1 (en) * | 2003-08-21 | 2005-02-24 | Ivan Lieberburg | Methods of improving the safety of zonisamide therapy |
US20050043704A1 (en) * | 2003-08-21 | 2005-02-24 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154034A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154032A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154033A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154036A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154037A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154035A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
WO2006023703A2 (en) * | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders |
EP1913935A1 (de) * | 2005-01-21 | 2008-04-23 | Teva Pharmaceutical Industries Ltd | Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung |
DE602006014607D1 (de) * | 2005-01-21 | 2010-07-15 | Teva Pharma | Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung |
US20080188510A1 (en) * | 2005-05-23 | 2008-08-07 | Eisai R & D Management Co., Ltd. | Novel methods using zonisamide |
EP1951212A2 (de) | 2005-11-22 | 2008-08-06 | Orexigen Therapeutics, Inc. | Zusammensetzungen und verfahren zur erhöhung der insulinsensitivität |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
TW201811315A (zh) | 2006-11-09 | 2018-04-01 | 美商歐瑞根治療有限公司 | 層狀醫藥調配物 |
KR20090090316A (ko) | 2006-11-09 | 2009-08-25 | 오렉시젠 세러퓨틱스 인크. | 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법 |
WO2009054543A1 (en) * | 2007-10-26 | 2009-04-30 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for parkinson's disease and movement disorders |
NZ589304A (en) | 2008-04-29 | 2012-03-30 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
EP4104824A1 (de) | 2012-06-06 | 2022-12-21 | Nalpropion Pharmaceuticals LLC | Zusammensetzung zur verwendung in einem verfahren zur behandlung von übergewicht und fettleibigkeit bei patienten mit hohem kardiovaskulärem risiko |
JP6155266B2 (ja) * | 2012-08-01 | 2017-06-28 | 大日本住友製薬株式会社 | ゾニサミドを含有する経皮吸収型製剤 |
WO2014119767A1 (ja) * | 2013-01-31 | 2014-08-07 | 沢井製薬株式会社 | テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤 |
US20180271838A1 (en) * | 2015-09-30 | 2018-09-27 | National University Corporation Nagoya University | Pharmaceutical composition for treating and/or preventing peripheral neuropathy or spinal cord injury |
EP3668508A1 (de) | 2017-08-19 | 2020-06-24 | FTF Pharma Private Limited | Orale pharmazeutische zusammensetzung mit zonisamid und verfahren zur herstellung davon |
EP3928771A1 (de) * | 2020-06-23 | 2021-12-29 | Laboratorios Lesvi, S.L. | Pharmazeutische zusammensetzungen von 1,2-benzisoxazol-3-methansulfonamid |
US20230202991A1 (en) | 2020-07-07 | 2023-06-29 | Sumitomo Pharma Co., Ltd. | Benzisoxazole derivative |
JP7324953B2 (ja) * | 2022-01-12 | 2023-08-10 | 住友ファーマ株式会社 | ベンゾイソキサゾール誘導体を含有する医薬組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
WO1989006129A1 (en) * | 1987-12-29 | 1989-07-13 | Dainippon Pharmaceutical Co., Ltd. | Agent for treating ischemic brain trouble |
US5830910A (en) * | 1995-10-23 | 1998-11-03 | University Of Kentucky Research Foundation | Cytochalasins useful in providing protection against nerve cell injury associated with neurodegenerative disorders |
-
1998
- 1998-12-21 CN CNB98812680XA patent/CN1149084C/zh not_active Expired - Fee Related
- 1998-12-21 WO PCT/JP1998/005757 patent/WO1999033465A1/ja active IP Right Grant
- 1998-12-21 CA CA002317044A patent/CA2317044C/en not_active Expired - Fee Related
- 1998-12-21 DE DE69830512T patent/DE69830512T2/de not_active Expired - Lifetime
- 1998-12-21 PT PT98961430T patent/PT1040830E/pt unknown
- 1998-12-21 KR KR10-2000-7007033A patent/KR100508393B1/ko not_active IP Right Cessation
- 1998-12-21 AT AT98961430T patent/ATE297204T1/de active
- 1998-12-21 JP JP2000526222A patent/JP3364481B2/ja not_active Expired - Lifetime
- 1998-12-21 US US09/582,433 patent/US6342515B1/en not_active Expired - Fee Related
- 1998-12-21 ES ES98961430T patent/ES2244103T3/es not_active Expired - Lifetime
- 1998-12-21 EP EP98961430A patent/EP1040830B1/de not_active Expired - Lifetime
-
2000
- 2000-10-30 HK HK00106879A patent/HK1029043A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR100508393B1 (ko) | 2005-08-17 |
EP1040830B1 (de) | 2005-06-08 |
EP1040830A4 (de) | 2002-10-23 |
CA2317044A1 (en) | 1999-07-08 |
HK1029043A1 (en) | 2001-03-23 |
DE69830512D1 (de) | 2005-07-14 |
KR20010015890A (ko) | 2001-02-26 |
CN1283113A (zh) | 2001-02-07 |
EP1040830A1 (de) | 2000-10-04 |
DE69830512T2 (de) | 2006-03-23 |
JP3364481B2 (ja) | 2003-01-08 |
CN1149084C (zh) | 2004-05-12 |
ES2244103T3 (es) | 2005-12-01 |
WO1999033465A1 (en) | 1999-07-08 |
US6342515B1 (en) | 2002-01-29 |
PT1040830E (pt) | 2005-08-31 |
CA2317044C (en) | 2008-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE297204T1 (de) | Heilmittel für neurodegenerative krankheiten | |
KR920019342A (ko) | 골질환 치료제 | |
KR960700742A (ko) | 아토피성질환 치료약(atopic disease remedy) | |
BG106095A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
MY127980A (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
ES2136723T3 (es) | Utilizacion de n-aril-metilen-etilen-diamino-triacetatos, n-aril-metilen-imino-diacetatos o n,n'-diaril-metilen-etilen-diamino-acetatos contra el estres oxidante. | |
BR0209812A (pt) | Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas | |
PT758241E (pt) | Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses | |
IL113941A (en) | Perfluoroalkyl ketone inhibitors of elastase processes for making the same and pharmaceutical compositions containing them | |
HUP0104709A2 (hu) | Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására | |
DE69400799D1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
ATE121295T1 (de) | Augentropfenarzneimittel. | |
BG105302A (en) | Means for improving cognition | |
FI972308A (fi) | 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi | |
FR2711140B1 (fr) | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. | |
ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
EP0744176A3 (de) | Arzneimittel zur Hemmung von Knochenschwund | |
AU4568400A (en) | Sphingomyelinase inhibitor | |
PT1150703E (pt) | Terapia de esclerose multipla com chaperonina 10 e beta-interferao | |
FR2786100B1 (fr) | Nouvelle application therapeutique de la nicergoline | |
EP0373771A3 (de) | Neue pharmazeutische Anwendungen von Cystatinen | |
GB9126874D0 (en) | Medicaments | |
BR9915292A (pt) | Associação, utilização de riluzol e composição farmacêutica. | |
DE69928685D1 (de) | Heilmittel und/oder vorbeugungsmittel gegen fettleibigkeit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEFA | Change of the company name | ||
UEP | Publication of translation of european patent specification |
Ref document number: 1040830 Country of ref document: EP |